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an estimated 2.4–4.5 million suffers 
from chronic wounds, including venous 
stasis ulcers, arterial ulcers, and diabetic 
wounds.[2] Chronic wounds fail to progress 
consistently through one or more stages of 
the normal wound healing cascade (i.e., 
hemostasis, local necrosis and inflamma-
tion, proliferation, and remodeling). In 
turn, these wounds are often associated 
with prolonged or excessive inflamma-
tion, persistent infections, and impaired 
vascularization and re-epithelization.[2] 
Early inflammation is triggered by infil-
tration of neutrophils and macrophages 
into the affected area, which mediate 
wound debridement by phagocytosis.[3,4] 
In addition, macrophages mediate fun-
damental innate immune processes and 
play multiple critical roles during wound 
healing.[5] This process is complemented 
with the release of cytokines, such as 
transforming growth factor-beta (TGF-β), 
vascular endothelial growth factor (VEGF), 
and fibroblast growth factor (FGF), which 
further recruit fibroblasts, endothelial 
cells, and keratinocytes to aid in angiogenesis, collagen depo-
sition, and wound contraction.[4,6–8] Classically-activated macro-
phages (M1) release proinflammatory cytokines during early 
stages of wound healing,[8,9] while the alternatively-activated 
macrophages (M2) pave the way for the resolution of the 
Chronic wounds are characterized by impaired healing and uncontrolled inflam-
mation, which compromise the protective role of the immune system and may 
lead to bacterial infection. Upregulation of miR-223 microRNAs (miRNAs) shows 
driving of the polarization of macrophages toward the anti-inflammatory (M2) 
phenotype, which could aid in the acceleration of wound healing. However, local-
targeted delivery of microRNAs is still challenging, due to their low stability. Here, 
adhesive hydrogels containing miR-223 5p mimic (miR-223*) loaded hyaluronic 
acid nanoparticles are developed to control tissue macrophages polarization 
during wound healing processes. In vitro upregulation of miR-223* in J774A.1 
macrophages demonstrates increased expression of the anti-inflammatory gene 
Arg-1 and a decrease in proinflammatory markers, including TNF-α, IL-1β, and 
IL-6. The therapeutic potential of miR-223* loaded adhesive hydrogels is also 
evaluated in vivo. The adhesive hydrogels could adhere to and cover the wounds 
during the healing process in an acute excisional wound model. Histological eval-
uation and quantitative polymerase chain reaction (qPCR) analysis show that local 
delivery of miR-223* efficiently promotes the formation of uniform vascularized 
skin at the wound site, which is mainly due to the polarization of macrophages to 
the M2 phenotype. Overall, this study demonstrates the potential of nanoparticle-
laden hydrogels conveying miRNA-223* to accelerate wound healing.
Local Macrophage Reprogramming
The ORCID identification number(s) for the author(s) of this article 
can be found under https://doi.org/10.1002/smll.201902232.
1. Introduction
Chronic diseases such as cardiovascular disorders and dia-
betes affect ≈133 million people in the US, which represents 
more than 40% of the total population.[1] From these patients, 
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inflammatory stage by secreting anti-inflammatory cytokines 
that promote wound healing.[8]
Macrophage reprogramming has been explored as a thera-
peutic strategy to promote wound healing due to its paramount 
role in tissue regeneration.[10,11] Therapies that regulate the 
induction of specific phenotype in macrophages have been 
used for the treatment of cardiovascular and inflammatory 
diseases and cancer.[12–15] However, there are limited studies 
on the effects of macrophage repolarization on wound healing 
in vivo. It has been demonstrated that prolonged inflamma-
tion in chronic wounds occurs due to the persistence of M1 
macrophages during the later stages of tissue repair.[16–18] 
Therefore, therapies that efficiently induce the polarization 
of macrophages toward the M2 phenotype could significantly 
improve the healing process. microRNAs (miRNAs), which are 
short single-stranded RNAs of 21–25 nucleotides, have gained 
significant interest for the treatment of a variety of diseases.[19] 
This is mainly due to their ability to target multiple genes in 
a particular pathway, leading to long-lasting effects at the 
molecular level.[20,21] Various miRNAs have been reported to be 
involved in different phases of wound healing, such as inflam-
mation, angiogenesis, and granulation.[20,22,23] For instance, 
miR-223 has been shown to act as a potent regulator of the 
inflammatory response by driving the polarization of inflam-
matory macrophages toward the tissue healing phenotype.[24] 
In addition, miR-223 expression has been shown to increase 
during the differentiation of granulocytes,[25] neutrophils,[26] 
monocytes,[27] megakaryocytes,[28] and eosinophils,[29] and 
decrease during erythrocyte and macrophage differentiation.[30] 
Therefore, efficient delivery of miR-223 to tissue macrophages 
may aid in the resolution of the inflammatory phase and pro-
mote angiogenesis and granulation. However, the development 
of gene therapies for wound healing based on this strategy has 
been hindered by the lack of efficient delivery systems.
Localized nucleic acid delivery, through the combination of 
a wound dressing and a nanocarrier, could enable convenient 
self-administration for patients, while avoiding issues with 
gastrointestinal tract absorption and hepatic first-pass metabo-
lism. Therefore, the use of localized drug delivery platforms 
can result in improving the bioavailability and maintenance 
of drug concentration within the therapeutic window. Besides, 
local delivery enables transmission of the most significant 
fraction of drug molecules to the target area, maximizing 
therapeutic potential and reducing systemic drug toxicity. In 
addition, polymeric hydrogel dressings loaded with different 
therapeutic agents, have been widely explored for the treat-
ment of cutaneous wounds.[31–33] This is mainly because 
hydrogel-based dressings can absorb the wound exudate, 
which in turn promotes infiltration of dermal and epidermal 
cells and the eventual re-epithelialization of the wound.[34] 
Our groups have recently developed biodegradable adhesive 
hydrogels that can provide a suitable environment for tissue 
regeneration.[35] Gelatin methacryloyl (GelMA)-based hydrogels 
have been shown to support the attachment, infiltration, and 
proliferation of cells that mediate wound re-epithelialization 
and healing.[35–37] Furthermore, the adhesive properties of these 
visible light cross-linkable hydrogels enable rapid and robust 
attachment to wounds of various shapes and sizes without the 
need for sutures or staples.
Although hydrogel-based dressings have been extensively 
used for the delivery of various therapeutic molecules, the effi-
cient delivery of miRNAs via bioadhesives for macrophage polar-
ization remains technically challenging. This can be primarily 
attributed to the specific characteristics of miRNAs, including 
their negative charge, rapid degradation by RNases, and a short 
half-life of ≈10 min in plasma.[38] Therefore, we aimed to develop 
a GelMA-based adhesive hydrogel for the local delivery of miR-
223 5p mimic (miR-223*) encapsulated in hyaluronic acid (HA)-
based nanoparticles (NPs). Two types of HA conjugates (i.e., 
HA-polyethyleneimine (HA-PEI) and HA-polyethylene glycol 
(HA-PEG)) were used to encapsulate miR-223* based on the 
electrostatic interaction between PEI and miRNA.[39] In par-
ticular, we used HA-PEG for the synthesis of the NPs to increase 
the residence time of these nanocomplexes in the circulation. 
HA, an anionic biopolymer that is found in the native extracel-
lular matrix (ECM), was used because of its nonimmunogenic 
and biocompatible nature, and its role in various stages of tissue 
regeneration/wound healing.[40,41] Moreover, previous reports 
have shown that HA can be easily cleared from the body through 
different excretion processes with a total turnover of about 5 g 
of HA per day in humans.[42] HA-based NPs also hold great 
potential for the specific targeting of inflammatory macrophages 
during sustained inflammation because of the specific interac-
tion between HA and membrane receptors such as CD44, which 
are highly expressed on macrophages.[43,44] Upon the formation 
of the hydrogels containing miR-223* loaded HA NPs, we opti-
mized the mechanical, physical, and adhesive properties of the 
hydrogels to ensure that they can adhere to the native skin and 
cover the wound during the healing process. Next, the concen-
tration of miR-223* loaded HA NPs was optimized to efficiently 
drive the polarization of macrophages in vitro. Last, we evalu-
ated the feasibility of using these adhesive hydrogels for local 
delivery of immunomodulatory agents in vivo using a murine 
model of acute excisional wounds. This animal model is gener-
ally used to assess the wound healing by evaluating granulation 
and vascularization at different time points.[45,46]
2. Results
In our previous studies, we demonstrated that GelMA-based 
adhesives possess optimal mechanical and adhesive proper-
ties to be used as a tissue sealant or bioadhesive.[47] In this 
study, GelMA was synthesized by direct reaction of methacrylic 
anhydride with gelatin as described before (Figure 1A).[37] Vis-
ible light cross-linkable GelMA hydrogels were then formed 
using Eosin Y as an initiator, the triethanolamine (TEA) as a 
co-initiator, and N-vinylcaprolactam (VC) as a comonomer. 
This visible light activated photoinitiator system helps circum-
vent the biosafety concerns of using UV light. We verified the 
chemical modification of gelatin with methacrylic anhydride 
via proton nuclear magnetic resonance (1H-NMR) (500 MHz; 
dimethyl sulfoxide-d6 (DMSO-D6)) analysis of gelatin and 
GelMA (Figure S1, Supporting Information). The appearance 
of peaks at δ = 5.3 ppm (peak a) and δ = 5.7 (peak b) ppm, 
corresponding to CC in the structure of methacrylate and 
methacrylamide groups, indicated conversion of gelatin to 
GelMA. We then characterized the mechanical properties of 
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GelMA hydrogels formed using different light exposure times 
(80–240 s). Our results indicated that the mechanical prop-
erties of hydrogels did not change for exposure times longer 
than 240 s, which could be due to the complete cross-linking 
of the prepolymer solution at 240 s (Figure S2, Supporting 
Information). The degree of cross-linking was calculated to 
be 87.8 ± 1.0% after 240 s of light exposure as measured by 
integration of the peaks at δ = 5.3 ppm (peak a) and 5.7 (peak 
b) ppm. This value did not show significant change at longer 
exposure times. Therefore, we selected 240 s of exposure time 
to photopolymerize the hydrogels throughout our study.
To prepare HA NPs, we conjugated 20 kDa HA with PEI 
or PEG, and used both HA conjugates at 50:50 (w/w) ratio to 
form miR-223* loaded NPs as described before.[39] The addi-
tion of HA-PEI increased the efficiency of encapsulation of 
miRNA (≈98%, as quantified by Ribogreen RNA assay) owing 
to the strong interaction between PEI and miRNA (Figure S3A, 
Supporting Information). Self-assembled NPs were formed 
at a ratio of 1:325 (w/w) miR-223* to HA conjugates in Dul-
becco’s phosphate-buffered saline (DPBS) with an average size 
of 160.0 ± 15.0 nm, a polydispersity index of 0.22 ± 0.02, and 
a surface charge of −13.0 ± 2.4 mV as measured by Malvern 
Zetasizer. The morphology of the NPs was further charac-
terized by transmission electron microscopy (TEM), which 
showed the presence of spherical shaped NPs, with the dark 
core representing uranyl acetate stained miRNA conjugated to 
Small 2019, 15, 1902232
Figure 1. Synthesis and mechanical characterization of NP-laden GelMA hydrogels. A) Schematic illustration of the process for the formation of NP/
miR-223*-laden GelMA hydrogels and the use of these adhesive hydrogels for wound healing. B) Representative TEM image of HA/miR-223* NPs 
made at 325:1 (w/w) ratio in DPBS. C) A representative confocal microscope image of Cy5.5-labeled NPs distribution in GelMA hydrogel. Red color 
represents HA NPs. D) Elastic modulus and E) compressive modulus of GelMA hydrogels containing varying concentrations of NPs in GelMA polymer 
%(w/w). Mechanical properties were measured after incorporation of both NP and NP/miR-223* (RNA), respectively. Data are represented as mean 
± SD (**p < 0.01 and ****p < 0.0001; n ≥ 3).
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PEI (Figure 1B). The negative surface charge of the HA NPs 
is consistent with a core–shell structure, where the miRNA-
complexed PEI constitutes the core of the nanocomplexes, 
while HA-PEG constitutes the outer shell. To evaluate the 
miR-223* NP formation, agarose gel electrophoresis was 
performed, and naked miR-223* was used as a control 
(Figure S3B, Supporting Information). The NPs loaded with 
miR-223* showed absence of miR-223* band, indicating the 
robustness of the nanocomplex. However, upon treatment with 
polyacrylic acid (PAA), the miRNA was released because of 
the decomplexation of the NPs. The NPs were also tested for 
nuclease stability, where naked miR-223* treated with RNase 
A and the PAA released miRNA showed complete degradation 
of miRNA (Figure S3B, Supporting Information). However, 
the miRNA condensed inside the HA NPs was protected from 
nucleases, as demonstrated by the absence of an miR-223* 
band. Overall, the modification of the HA polymer backbone 
with cationic branched PEI helped decrease the overall nega-
tive charge of the HA biopolymer and promote nucleic acid 
encapsulation (HA–PEI/miRNA nanoparticles) via electrostatic 
interactions.[39,40,48] The high counterion density of these nano-
particles is also known to promote endosomal escape following 
cellular internalization via the “proton-sponge effect.”[49] Fur-
thermore, the PEG-modified HA polymer backbones were able 
to self-assemble with miRNA-loaded HA–PEI, yielding mul-
tifunctional nanoparticle complexes that could help increase 
the residence time of these nanocomplexes in the circulation. 
Taken together, these results confirmed that the conjugation of 
miRNA to PEI led to increased half-lives and lower degradation, 
while also allowing controlled release of the nucleic acids upon 
degradation of the nanocomplexes.
We next evaluated the effect of the addition of different con-
centrations of NPs on the mechanical properties of GelMA 
hydrogels. Our results revealed no significant changes in the 
mechanical properties of GelMA hydrogels after the incorpora-
tion of NPs up to 5.0%(w/w) with a compressive modulus of 
30.8 ± 2.5 kPa, an elastic modulus of 95.9 ± 1.4 kPa, and an 
extensibility of 18.9 ± 1.8% (Figure 1D,E). The formulation of 
the precursor was optimized to yield hydrogels with an elastic 
modulus in the range of the native dermis (≈88–300 kPa) and a 
compressive modulus in the range of physiological soft tissues 
(10–200 kPa).[50,51] We further characterized the structure of 
the hydrogels containing NPs using scanning electron micro-
scopy (SEM) analysis, which showed no significant differences 
between the porous structure of the hydrogels with and without 
NPs (Figure S4, Supporting Information). Due to the small size 
of NPs (≈160.0 nm), the microarchitecture and consequently 
the physical properties of the NP-laden hydrogels (GelMA/NP) 
remained unchanged.
Conventional methods for wound closure such as sutures, 
mechanical fasteners, and staples are often associated with 
increased localized stress and trauma, as well as a higher risk 
of infection. In contrast, a hydrogel-based adhesive can strongly 
attach to the wound to act as a physical barrier to protect it from 
infection and as a depot to support the migration of cells to 
accelerate the rate of healing. An ideal adhesive should with-
stand the pressure exerted by the underlying tissue and fluids, 
seal the boundaries of a wound, and resist shear stresses. To 
evaluate the adhesive properties of the hydrogels, we performed 
burst pressure, wound closure, and lap shear tests based on 
modified American Society for Testing and Materials (ASTM) 
standard tests (Figure 2). Burst pressure tests were carried out 
to evaluate the resistivity of hydrogels against the pressure 
exerted by the underlying tissue and fluids. For this, air was con-
tinuously pumped into a custom-designed burst pressure appa-
ratus. The hydrogels and commercial adhesives were applied to 
cover defects formed on porcine intestine sheets as a biological 
substrate (Figure 2A). Wound closure tests were conducted to 
investigate the ability of the hydrogels to seal the boundaries 
of a wound upon tensile stress. The hydrogels and commercial 
adhesives were applied on top of a 1 mm defect formed between 
two pieces of porcine skin as a biological substrate (Figure 2B). 
Last, lap shear tests were performed to evaluate the ability of 
the hydrogels to withstand shear stress (Figure 2C). Our results 
demonstrated that the adhesion of GelMA hydrogels containing 
NPs to physiological tissues was stronger than those observed 
for commercially available adhesives such as Evicel and Coseal 
(Figure 2D–F). In this regard, previous works have shown that 
GelMA-based adhesives exhibited high adhesion to different 
tissue surfaces due to the mechanical interlocking between 
GelMA and the native tissue, and covalent bonding triggered 
by radicals generated during photo-crosslinking.[35] In addition, 
the presence of NPs in the hydrogel network did not affect the 
adhesion properties of the hydrogel.
Multiple factors can affect the diffusion rate of molecules 
or NPs from polymeric networks, such as the type of polymer, 
pore size, the geometry of the particles (size and shape), prepa-
ration technique, particle concentration, and physiological con-
ditions. In our system, the diffusion rate of NPs was highly 
dependent on the infiltration of water into the polymeric struc-
ture (swelling) and the dissociation of polymeric bonds (degra-
dation), which aids in the release of NPs from the hydrogels. 
Therefore, we first assessed the swellability and degradation 
rate of the GelMA/NP hydrogels in vitro. Our results showed 
that the hydrogels reached their maximum swelling ratios 
after 24 h, which corresponded to 5.17 ± 0.32 for GelMA/
NP hydrogel containing 5.0%(w/w) NPs. These values were 
in the range of GelMA hydrogels, which indicated that the 
incorporation of NPs did not alter the swellability of GelMA/
NP hydrogels (Figure 3A). In particular, the high water-uptake 
capacity of GelMA-based hydrogels could mediate the absorp-
tion of wound exudates and induce the deposition of ECM com-
ponents that promote cellular function and tissue regeneration 
in vivo. On the other hand, GelMA/NP hydrogels exhibited 
only 20% weight loss after 14 days of incubation in DPBS in 
vitro (Figure 3B). This observation suggested that GelMA/NP 
can retain structural stability throughout the different stages of 
wound healing.
Kinetics of in vivo degradation for GelMA hydrogels may 
differ due to the presence of proteases in the wound area. In 
particular, collagenase type II (MMP-8) is the predominant 
proteolytic enzyme involved in the healing of normal and non-
healing wounds.[52] Therefore, we evaluated the release rate of 
miRNA loaded NPs (NP/miRNA) from GelMA hydrogels in 
the presence and absence of collagenase type II. Our results 
showed 100% release of NP/miRNA, as measured by Ribogreen 
RNA assay, from hydrogels containing 5%(w/w) NPs after 48 h 
incubation in DPBS at 37 °C and in the absence of collagenase 
Small 2019, 15, 1902232
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type II (Figure 3C). However, 89 ± 8 and 43.9 ± 10.1% release 
rates were observed for hydrogels loaded with 2.6%(w/w) and 
1.3%(w/w) NPs, respectively. These results demonstrated 
that different doses of miRNA could be obtained by varying 
the concentrations of NPs that were loaded into the GelMA/
NP hydrogels. Our results also showed that the diffusion 
rate of NPs released from the porous hydrogel network was 
highly dependent on the initial concentration of NPs used to 
synthesize the scaffolds. The burst release observed during the 
first 10 h could be related to the higher concentration of NPs 
that existed closer to the surface of the hydrogels and were in 
contact with the fluid. Moreover, a sustained release pattern was 
observed after 10 h of incubation for almost all concentrations 
tested, which corresponded to the NPs that were located further 
away from the surface of hydrogels. Overall, the results showed 
that the release rate for 5%(w/w) NPs in GelMA hydrogel can 
Small 2019, 15, 1902232
Figure 2. Adhesive properties of NP-laden GelMA hydrogels. A) A representative image of burst pressure measurement setup. B) A representative 
image of wound closure measurement setup and C) a representative image of burst lap shear setup. D) In vitro burst pressure measurement of hydro-
gels with varying concentrations of NPs and two commercially available adhesives. E) In vitro adhesion strength measurement of hydrogels with varying 
concentrations of NPs and two commercially available adhesives. F) In vitro shear strength of hydrogels with varying concentrations of NPs and two 
commercially available adhesives. Data are represented as mean ± SD (*p < 0.05, **p < 0.01, and ****p < 0.0001; n ≥ 3).
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potentially be used to control the macrophage polarization in 
the wound microenvironment during early stages of wound 
healing. Previous works have shown that inflammation takes 
place immediately after scab formation during the early stages 
of the healing process (1–3 days). In addition, our results dem-
onstrated that hydrogels with 5%(w/w) NPs/miR-223* exhibited 
100% cumulative release after 48 h (Figure 3C). These observa-
tions indicated that 5%(w/w) scaffolds could be used to induce 
macrophage polarization during relevant clinical time frames 
in vivo and thus, this formulation was selected for further in 
vitro and in vivo studies. We then evaluated the effect of enzy-
matic degradation on the release profile of NPs/miR-223* from 
GelMA hydrogels. Our results showed that hydrogels incubated 
with DPBS containing 2.5 µg mL−1 of the enzyme exhibited 
32.8 ± 5.3% weight loss on day 14 (Figure S5, Supporting Infor-
mation). To assess the integrity of miRNAs during the release 
process, we studied the release of miRNA from the hydrogels in 
the elevated concentration of collagenase type II at 100 µg mL−1 
(Figure 3D). Our results indicated 100% release of miRNA for 
all concentrations of NPs in GelMA 48 h post-incubation, owing 
to the complete degradation of the hydrogels.
To assess the cytotoxicity of GelMA/NP hydrogels, we per-
formed in vitro tests by 3D encapsulation of NIH3T3 fibroblasts 
within the hydrogels (Figure S6, Supporting Information) and 
by exposing J774A.1 macrophages to the hydrogels using a 
transwell system (Figure S7, Supporting Information). Quanti-
fication of live/dead stained images revealed >97% viability for 
both cell lines (Figures S6D and S7C, Supporting Information). 
In addition, metabolic activity increased consistently during 
5 days of culture (Figures S6E and S7D, Supporting Informa-
tion). These results revealed that GelMA/NP hydrogels can 
efficiently support the growth and proliferation of cells without 
eliciting any cytotoxic responses in vitro. Previous works have 
also shown that the administration of HA-PEI NPs had minimal 
systemic toxicity and a high clearance rate in vivo.[53]
We next evaluated the ability of NP/miR-223* released from 
GelMA/NP/miR-223* hydrogels to be internalized by macro-
phages in vitro (Figure 4). First, we investigated the internaliza-
tion of NP/Cy3-labeled miRNA released from GelMA hydrogels 
into J774A.1 macrophages. We have previously demonstrated 
that HA NPs could transfect J774A.1 macrophages via CD44 
mediated internalization and its interaction with HA.[43] The 
intracellular transfection of Cy3-labeled miRNA released from 
5%(w/w) NPs in GelMA hydrogels led to a very strong signal 
after 24 h of incubation, followed by a gradual decrease 48 h 
post-incubation (Figure 4A). Next, we performed miR-223 spe-
cific Taqman assay for quantification of transfected miR-223*. 
First, the macrophages were induced to the M1 phenotype by 
incubation with lipopolysaccharide (LPS) and interferon gamma 
(IFN-γ). The M1 induced macrophages were then incubated 
with GelMA/NP/miR-223* and GelMA/NP/negative miRNA 
hydrogels, formed in transwells, and were cultured for 24, 
and 48 h. Basal expression levels of miR-223* in J774A.1 mac-
rophages were found to be very low with no significant increase 
upon LPS/IFN-γ induction. In contrast, miR-223* levels in M1 
macrophages incubated with GelMA/NP/miR-223* were sig-
nificantly higher, with a 1541 ± 340-fold increase after 24 h of 
incubation as compared to the control (Figure 4B). This was 
then followed by a gradual decrease to 861 ± 216-fold after 
48 h, respectively, which was indicative of a higher release of miR-
223* 24 h after incubation. Moreover, we observed 200 ± 51-fold 
increase in the miR-223 expression of M1 macrophages trans-
fected with NP/miR-223* released from 1.3%(w/w) GelMA/
NP/miR-223* compared to the GelMA/NP/negative miRNA 
group 48 h post-incubations (Figure S8B, Supporting Informa-
tion). These results demonstrated the efficient transfection and 
Small 2019, 15, 1902232
Figure 3. Physical properties of NP-laden GelMA hydrogels and in vitro release profile of NP/miRNA from hydrogels. A) Swelling ratio and B) degra-
dation rate of GelMA hydrogels loaded with varying concentrations of NPs in GelMA polymer in DPBS buffer (pH 7.4). C) In vitro release profile of 
miRNA released from GelMA/NP/miRNA hydrogels in DPBS and D) enzyme induced release of miRNA from GelMA/NP/miRNA in the presence of 
100 µg mL−1 collagenase type II in DPBS, 48 h post-incubation.
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specific expression of miR-223 in J77A4.1 macrophages using 
NP/miR-223* released from GelMA/NP/miR-223*. 5%(w/w) 
GelMA/NP/miR-223* hydrogels were used for gene expression 
and in vivo studies, since we achieved 100% cumulative release 
of NPs/miR-223* after 48 h, which coincided with the onset of 
the inflammatory stage of the healing process. Using 5%(w/w) 
Small 2019, 15, 1902232
Figure 4. miRNA transfection and macrophage repolarization studies in J774A.1 macrophages using GelMA/NP/miR-223* hydrogels in a transwell 
setup. A) Representative fluorescent microscope images for transfection of Cy3-labeled miRNA released from GelMA/NP/miRNA hydrogel, at the 
concentration of 5.0%(w/w), in J774A.1 macrophages on 24 and 48 h post-incubation. Green color represents Cy3-labeled miRNA and blue color 
represents cell nuclei, respectively (Scale bar = 200 µm). B) miR-223 expression was quantified by miR-223 specific Taqman assay performed in 
J774A.1 macrophages on 24 and 48 h post-incubation with GelMA/NP/Neg miRNA and GelMA/NP/miR-223* hydrogels. The M1 represents cells that 
received LPS + IFN-γ treatment for 16 h before incubation with either groups. Neg miRNA represents negative control miRNA and miR-223* represents 
miR-223 5p mimic. The gene expression level was normalized to untreated cells that did not receive any treatment. U6 snRNA was used as endog-
enous housekeeping gene. C) In vitro macrophage repolarization. qPCR analysis of Arg-1 (M2 marker)/iNOS-2 (M1 marker) gene expression was 
conducted on 24 and 48 h post-incubation with GelMA/NP/Neg miRNA or GelMA/NP/miR-223* hydrogels. β-actin was used as a housekeeping gene. 
D–F) Anti-inflammatory effects of miR-223* transfection in J774A.1 macrophages. Decreased expression of proinflammatory cytokine (TNF-α, IL-6, 
and IL-1 β mRNA) levels was observed upon 24 and 48 h post-incubation with GelMA/NP/Neg miRNA and GelMA/NP/miR-223* hydrogels. The 
gene expression level was normalized to untreated cells that did not receive any treatment. β-actin was used as a housekeeping gene. *p < 0.05. Data 
are represented as mean ± SD (*p < 0.05 and **p < 0.01, compared to GelMA/NP/Neg miRNA group with n = 4 individual experiments per group).
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GelMA/NP/miR-223* hydrogels also enabled us to study the 
immunomodulatory potential of the scaffolds following a single 
administration of each experimental treatment, with no subse-
quent doses.
Macrophage polarization following transfection of miR-
223* was also evaluated by measuring the relative levels of 
expression of Arg1/iNOS2 (M2 or anti-inflammatory/M1 or 
proinflammatory) after 24 and 48 h of incubation with 5%(w/w) 
GelMA/NP/miR-223* hydrogels. Our results revealed a seven-
fold and a five-fold increase in the Arg1/iNOS2 ratios 24 and 
48 h post-incubation with GelMA/NP/miR-223* hydrogels, 
respectively, compared to the control. These observations were 
indicative of the polarization of M1 induced macrophages 
toward the anti-inflammatory phenotype via miR-223* trans-
fection (Figure 4C). These results were further confirmed by 
evaluating the expression levels of proinflammatory cytokines 
up to 48 h (Figure 4D–F). The results showed that the levels 
of expression of TNF-α, IL-6, and IL-1β were decreased signifi-
cantly 24 h post-incubation with GelMA/NP/miR-223* hydro-
gels, compared to the control (Figure 4D–F). TNF-α, IL-6, and 
IL-1β mediate the inflammatory phase and have been reported 
to suppress endothelialization, which could then impair the 
wound healing process. Taken together, these results confirmed 
the successful polarization of M1 macrophages toward the M2 
state using GelMA/NP/miR-223* hydrogels in vitro.
After we confirmed the ability of GelMA/NP/miR-223* 
hydrogels to drive macrophage polarization in vitro, we evalu-
ated their efficacy to modulate inflammatory responses and 
wound healing in vivo, using a murine model of excisional 
wounds. Hydrogels were photopolymerized on top of wounds 
formed on the skin on the back of the animals on day 0. The 
borders of the wounds were immobilized with silicon splints 
to prevent the normal contraction of the wound and to better 
evaluate the degree of re-epithelization and granulation. Ani-
mals were divided into four treatment groups: 1) DPBS treated 
(DPBS), 2) pristine GelMA hydrogels (GelMA), 3) NP/negative 
miRNA-laden GelMA hydrogels (Neg miRNA), and 4) NP/miR-
223*-laden GelMA hydrogels (miR-223*). GelMA hydrogels 
containing 5%(w/w) NPs/miR-223* were chosen for in vivo 
studies due to their ability to induce macrophage polarization 
in vitro within 2 days after incubation. Visual inspection of 
the wounds revealed that the percentage of wound closure for 
miR-223* (i.e., 95.8 ± 4.3%) treatment group was significantly 
higher than Neg miRNA (66.7 ± 2.9%), GelMA (60.8 ± 3.5%), 
and DPBS (44.9 ± 7.9%) treated wounds (Figure 5A,B). These 
results were further confirmed by histological analysis, which 
showed that miR-223 5p mimic effectively promoted wound clo-
sure and healing, as demonstrated by the formation of new skin 
on day 12 post-surgery (Figure 5C). Quantification of pannic-
ulus carouses (PC) muscle closure under the fatty tissue layer 
based on Hematoxylin and Eosin Y (H&E) staining showed 
96.3 ± 3.5% closure for miR-223*, which was significantly 
higher than wounds treated with Neg miRNA (49.7 ± 5.1%), 
GelMA (38.7 ± 2.5%), and DPBS (45.4 ± 7.1%) (Figure 5E).
The formation of new blood vessels (i.e., angiogenesis) 
occurs during the proliferative phase of wound healing, 
and ≈4–7 days after tissue disruption. During this process, 
new vascular sprouts extend to form capillary networks that 
mature into fully-formed blood vessels. In order to visualize 
the migration and organization of vascular endothelial cells at 
the center of the wounds, we performed immunofluorescent 
staining (IFS) against the angiogenesis-related marker CD31 
(Figure 5D). Our results demonstrated that miR-223* treated 
group showed a >2-fold increase (p < 0.01) in the expression 
of CD31, as compared to the Neg miRNA group (Figure 5F). 
Quantification of CD31/DAPI fluorescent images revealed 
1917 ± 175 microvessels per viewing field (=2.5 mm) for 
miR-223*, which was significantly higher than the wounds 
treated with Neg miRNA (769 ± 80), GelMA (638 ± 34), and 
DPBS (329 ± 138) (Figure 5F). These results were in accordance 
with previous studies that have shown that the upregulation of 
miR-223 in the bone marrow promotes the proliferation and 
infiltration of hematopoietic cells to the wound site.[54] Further-
more, M2 macrophages have been shown to produce proan-
giogenic molecules (i.e., FGF and VEGF) that can induce the 
formation of new blood vessels.[55–57]
Collagen formation plays a key role during wound healing 
by enabling cell migration and acting as a foundation for ECM 
deposition during the proliferative phase of wound healing. 
Therefore, the formation of collagen-rich ECM can be an 
indicator of the transition from the inflammatory stage to the 
subsequent phases of the healing process. To evaluate collagen 
formation, we used Masson’s trichrome (MTC), a histological 
staining technique in which collagen is stained in blue, while 
cell bodies, muscle, and keratin are stained in red (Figure 6A). 
Histological assessment via MTC revealed a two-fold increase in 
the thickness of the collagen layer in wounds treated with miR-
223* (1.7 ± 0.1 mm), as compared to the wounds treated with 
Neg miRNA (0.8 ± 0.1 mm), GelMA (0.4 ± 0.0 mm), and DPBS 
(0.0 ± 0.0 mm) on day 12 (Figure 6B). Thicker collagen layer at 
day 12 in Neg miRNA treated wounds as compared to GelMA 
treated wounds was most likely due to nonspecific target effects 
of Neg miRNA. However, we did not observe any other sign of 
better wound healing in Neg miRNA treated wounds throughout 
the assessment of wound healing markers. Collagen deposi-
tion was observed as early as day 5 for wounds treated with 
miR-223* as opposed to the control treatments, including Neg 
miRNA treated wounds (Figure 6A). Our results showed that 
GelMA/NP/miR-223* hydrogels exhibit a remarkably high-water 
uptake capacity and could support cell attachment and growth in 
vitro. In turn, these characteristics could allow the drainage of 
the wound exudate and cellularization of the scaffold in vivo, as 
confirmed by both MTC and H&E stained images taken at day 
5 post-surgery (Figure 6A; Figure S9, Supporting Information). 
The formation of granulation tissue was also evaluated on H&E 
stained slides for GelMA, Neg miRNA, and miR-223* hydrogel-
treated wounds (Figure S9A,B, Supporting Information). Simi-
larly, MTC stained samples taken at day 5 post-surgery revealed 
significant tissue ingrowth (red stain) within the polymeric scaf-
folds for GelMA, Neg miRNA, and miR-223*-treated wounds 
(Figure S9C, Supporting Information).
Inflammation is triggered during the early stages of wound 
healing via the infiltration of neutrophils and macrophages, 
≈48 h after tissue disruption. It is mainly mediated by proin-
flammatory cytokines secreted by M1 macrophages in response 
to exogenous or endogenous signals. Therefore, we performed 
IFS against the pan-macrophage marker F4/80, as well as the 
M2 macrophage marker CD206 (C-Type Mannose Receptor 
Small 2019, 15, 1902232
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Figure 5. Wound area and histological analysis of wounds on 2 and 12 days after GelMA/NP/miR-223* hydrogel treatment. A) Representative images 
of the wounds treated with DPBS, GelMA, Neg miRNA, and miR-223* after 0 and 12 days of treatment. Black dashed lines demarcate the boundaries 
of wound. *Images for animals at day 12 were acquired after removal of the silicon splint to highlight the extent of wound healing. B) Quantitative 
evaluation of wound area after 12 days of treatment. C) H&E-stained sections of a full-thickness wound after 12 days of treatment with DPBS, GelMA, 
Neg miRNA, and miR-223*. Black arrows indicate the edges of the panniculus carnosus (PC) muscle. D) Representative immunofluorescent stained 
images were taken from the center of wound after 12 days of treatment (black square indicates the area for vascularization evaluation). Endothelial 
cells are shown in red (CD31) and nuclei are shown in blue (DAPI). E) Quantification of tissue regeneration evaluated by PC muscle closure. F) Quan-
tification of microvessel formation per viewing field (=2.5 mm) for the different treatment groups. Data are represented as mean ± SD (*p < 0.05 and 
**p < 0.01; n ≥ 3).
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1) to assess the ability of GelMA/NP/miR-223* to selectively 
direct macrophage polarization toward the M2 phenotype 
(Figure 7A–C). For this, the ratio of M2 macrophages over total 
macrophages was calculated based on IFS stained tissue sections. 
IFS against CD206 revealed a significant increase in the ratio 
of M2 macrophages over total macrophages (Figure 7C). These 
results confirmed that local polarization of macrophages was 
directed toward the M2 phenotype for miR-223* treated wounds. 
We did not observe any positive fluorescent staining against both 
F4/80 and CD206 on day 12, which was indicative of macrophage 
withdrawal during the latter stages of wound healing. In parallel, 
we further quantified the change in the relative levels of expres-
sion of M1 (i.e., iNOS2) and M2 (i.e., Arg1) markers via quan-
titative polymerase chain reaction (qPCR) analysis from tissue 
samples retrieved on days 2 and 5 post-surgery (Figure 7D). 
Our results revealed a significant increase in the expression of 
M2-specific genes on days 2 and 5 postsurgery, as demonstrated 
by the higher ratio of Arg1/iNOS2 in wounds treated with miR-
223* as compared to the controls (Figure 7D). Furthermore, the 
slight increase observed in the Arg1/iNOS2 ratio for GelMA 
and Neg miRNA treated groups could be explained due to the 
natural repolarization of macrophages from the M1 toward 
the M2 phenotype during later stages of wound healing. Taken 
together, these observations suggest that NP/miR-233 5p mimic 
loaded hydrogels not only increased the level of macrophage 
infiltration but also effectively mediated the local polarization 
of macrophages toward the M2 phenotype in vivo. This in turn 
led to comparatively better healing for wounds treated with 
Small 2019, 15, 1902232
Figure 6. Collagen deposition and granulation tissue formation at 5 and 12 days postsurgery. A) Representative images of Masson’s trichrome (MTC) 
stained sections of a full-thickness skin wound after 5 and 12 days of treatment with DPBS, GelMA, Neg miRNA, and miR-223* hydrogels (black 
dashed lines indicate the boundaries of wound). Cell migration is observed on day 5 postsurgery inside the hydrogels using MTC staining at the wound 
and hydrogel intersection (black dashed boxes). B) Quantification of the collagen thickness at the center of the wound (blue stain). miR-223* treated 
wounds showed higher collagen deposition as compared to the control groups after 5 and 12 days of treatment. Data are represented as mean ± SD 
(*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001; n ≥ 3).
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NP/miR-233 5p mimic (miR-223*), as demonstrated by 
increased re-epithelization, formation of granulation tissue, 
and vascularization at the wound area.
3. Conclusion
miRNAs have emerged as a potential therapy for the treat-
ment of non-healing wounds, due to their pivotal role in the 
modulation of cellular processes involved in wound healing. 
Among all reported miRNAs, miR-223 has been shown to be 
a potent regulator of bone marrow-derived cells. However, its 
role in tissue regeneration/wound healing has not been fully 
explored mainly due to the limitations of current delivery 
systems. Here, we developed a delivery system using a mac-
rophage-targeting HA NP-laden adhesive hydrogel. Both the 
adhesive hydrogel and the miR-223* loaded NPs were synthe-
sized from highly biocompatible and naturally-derived biopoly-
mers (i.e., GelMA and HA, respectively). The main advantage 
Small 2019, 15, 1902232
Figure 7. Immunohistological and quantitative analysis of wounds for macrophage evaluation after 2 and 5 days of treatment. A,B) Representative 
immunofluorescent stained images for total macrophage and M2 phenotype expression from the center of wound after 2 days of treatment with DPBS, 
GelMA, Neg miRNA, and miR-223* hydrogels. Total macrophage marker (F4/80) and M2 macrophage (antimannose receptor antibody) are shown in 
red color. Blue color represents nuclei (DAPI) and green color represents GelMA. C) Quantitative analysis of M2 macrophages/total number of mac-
rophages, per viewing field after 2 and 5 days of treatment (only red stained cells in the wound area are counted, that is the area between two white 
dashed lines) (viewing field = 2.5 mm). D) qPCR analysis of Arg1/iNOS2 mRNA expression for wound biopsies after 2 and 5 days of treatment relative 
to GAPDH expression. Data are represented as mean ± SD (*p < 0.05 and **p < 0.01; n ≥ 3).
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of the hydrogel precursor is its ability to be readily delivered 
to wounds with varying shapes and sizes and be rapidly photo-
crosslinked in situ via exposure to visible light. The high encap-
sulation and transfection efficiency of the HA NPs inside the 
adhesive hydrogels allowed the use of relatively small concentra-
tions of miR-223*. HA-based NPs loaded with miR-223* were 
able to efficiently induce the polarization of M1 macrophages 
toward the anti-inflammatory M2 state both in vitro and in vivo, 
accompanied by accelerated tissue regeneration rate. Histo-
logical evaluation of explanted tissue samples showed that the 
GelMA/NP/miR-223* hydrogels could drive wound healing by 
not only triggering the resolution of the inflammatory phase 
but also by promoting the formation of new vascularized skin 
tissue. Our adhesive hydrogel system provides a suitable plat-
form to deliver different nucleic acids for gene therapy.
Future work will focus on evaluating the ability of this 
system to elicit macrophage polarization and wound healing 
using a more physiologically relevant model of chronic non-
healing wounds. This is mainly because there are significant 
differences at the cellular and molecular level between the 
wound microenvironment in normal subjects when compared 
to patients exhibiting non-healing wounds. Furthermore, we 
will explore the incorporation of additional miRNAs that can 
modulate the function of other inflammatory cells involved 
in wound healing. We also aim to further characterize global 
changes in gene expression occurring in macrophages during 
in vivo polarization toward the anti-inflammatory phenotype. 
Last, chronic wounds are highly susceptible to microbial infec-
tion, and the incorporation of an antimicrobial strategy based 
on different biocidal agents such as ZnO NPs or antimicrobial 
peptides will be explored. Moreover, diabetic wounds create a 
fertile environment for biofilm formation because the necrotic 
tissue and debris are easily susceptible to infection and bacte-
rial colonization. The presence of biofilm creates a self-per-
petuating cycle, prolonging the existence of macrophages and 
neutrophils in the wound bed. Therefore, the adhesive wound 
dressing can be used as a reservoir to deliver novel antibacterial 
agents that can prevent the growth of drug-resistant microbial 
infections. Taken together, our results showed the remarkable 
potential of NP/miR-233*-laden adhesive hydrogels to be used 
as sutureless, regenerative, and immunomodulatory wound 
dressings to promote the healing of chronic wounds.
4. Experimental Section
Materials: Sodium hyaluronate (HA, 20 kDa) was purchased from 
Lifecore Biomedical Co. (Chaska, MN). Branched polyethyleneimine 
(bPEI, 10 kDa) and MTC Stain Kit were purchased from Polysciences 
Inc. (Warrington, PA). Gelatin from cold water fish skin, methacrylic 
anhydride (MA), Eosin Y disodium salt, TEA, VC, H&E solutions, N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC), 
N-hydroxysuccinimide (NHS), LPS, 3-trimethoxysilylpropyl methacrylate 
(TMSPMA), and 4-morpholineethanesulfonate (MES) were purchased 
from Sigma-Aldrich. Collagenase type II was purchased from Worthington 
Biochemical Co. Monofunctional polyethyleneglycol amine (PEG-amine, 
2 kDa) was purchased from Creative PEG Works (Winston Salem, NC). 
Dulbecco’s modified Eagle medium (DMEM) was purchased from Cellgro 
(Manassas, VA) and fetal bovine serum (FBS) was obtained from HyClone 
(Logan, UT). Murine IFNγ was obtained from PeproTech (Rocky Hill, NJ). 
4′,6-diamidino-2-phenylindole (DAPI), Alexa-Fluor 488-phalloidin, and 
live/dead viability kit were purchased from Invitrogen (San Diego, CA). 
mmu-mirVana miR-223 5p mimic (Thermo Fischer scientific, catalogue 
no. 4464066; Assay ID: MC14755), mirVana miRNA mimic negative 
control #1 (Thermo Fischer scientific, catalog no. 4464058), TaqMan 
probes specific for miR-223 (Thermo Fischer scientific, catalog no. 
4427975), nuclease free water, and penicillin/streptomycin antibiotics 
were purchased from Life Technologies (Woburn, MA). Primers specific 
for iNOS-2, TNF-α, Arg-1, IL-1β, IL-6, and β-actin were purchased from 
Thermo Fisher Scientific (Waltham, MA). Quant-iT RiboGreen RNA assay 
kit was purchased from Thermo Fischer scientific. Quick-RNA isolation 
kit was purchased from Zymoresearch (Irvine, CA). The iScript Reverse 
Transcription Supermix and iTaq Universal SYBR Green Supermix were 
purchased from Bio-Rad (Hercules, CA).
Preparation and Characterization of NPs/miRNA: HA-PEI and HA-PEG 
conjugates were synthesized by coupling reaction between HA (20 kDa) 
and bPEI (10 kDa) or PEG-amine (2 kDa), respectively, in the presence 
of EDC/NHS, as described previously.[40] Briefly, for the synthesis of HA–
PEI conjugate, HA (100 mg) was dissolved in 1 m NaCl. EDC (50 mg) 
and NHS (50 mg) were added, and the solution was stirred for 30 min 
at room temperature. PEI (15 mg) was added, and the pH of the final 
solution was adjusted to 7. After stirring overnight at room temperature, 
the solution was dialyzed first against 1 m NaCl for 8 h and then against 
deionized water for 24 h using a cellulose dialysis membrane (molecular 
weight (MW) cutoff ≈12–14 kDa). Alternatively, for the synthesis of HA–
PEG conjugate, 100 mg of HA was dissolved in 20 × 10−3 m MES buffer 
and 500 × 10−3 m NaCl, pH 6. 50 mg of PEG-amine was added, and the 
solution was stirred for 15 min. Next, EDC (50 mg)/NHS (50 mg) solution 
(dissolved in 20 × 10−3 m MES buffer and 500 × 10−3 m NaCl, pH 6) was 
added to the HA/PEG-amine solution and stirred overnight at room 
temperature. The solution was then dialyzed against deionized water 
for 24 h using a cellulose dialysis membrane (MW cutoff ≈12–14 kDa). 
Both dialyzed solutions of HA-PEI and HA-PEG were frozen at −80 °C 
overnight, lyophilized, and stored at −20 °C until used for experiments.
HA-PEI/HA-PEG NPs were prepared by mixing HA-PEI and HA-PEG 
at a 1:1 ratio in DPBS. miR-223 5p mimic (miR-223*) was added to the 
HA-PEI/HA-PEG solution at a 1:325 (w/w) ratio, vortexed, and incubated 
for 20 min at room temperature. The miRNA encapsulation efficiency was 
measured by an indirect method. Briefly, the NPs were centrifuged for 
20 min at 13 000 rpm, and the unencapsulated miRNA was measured in the 
supernatant using Ribogreen RNA assay (Thermoscientific). The average 
particle size, polydispersity index, and zeta potential were measured using 
Malvern Zetasizer (Westborough, MA). The morphology of the NPs was 
also analyzed using TEM (JEOL, Peabody, MA). For TEM, the samples 
were prepared by adding a drop of NPs in DPBS on a Formvar/Carbon film 
grid followed by air-drying and 2% uranyl acetate staining.
Synthesis and Mechanical Characterization of NP/miRNA-Laden GelMA 
Adhesives: GelMA was synthesized as described previously.[58] Briefly, 
gelatin from cold water fish skin (10 g) was dissolved in DPBS at 50 °C. 
8%(v/v) MA was added dropwise under continuous stirring at 50 °C. 
After 3 h, the solution was diluted with DPBS to stop the reaction. The 
diluted solution was dialyzed against distilled water at 50 °C for 5 days. 
The resulting solution was then filtered under sterile conditions, frozen 
at −80 °C overnight, and lyophilized for 4 days. The lyophilized GelMA 
was dissolved in a solution containing TEA (3.75%(w/v)) and VC 
(2.5%(w/v)) in DPBS. NPs were formed and kept at 4 °C prior for cross-
linking. NP solutions with varying concentrations were mixed with the 
GelMA precursor solution at a 1:1 (v/v) ratio. Eosin Y disodium salt 
(1 × 10−3 m) was dissolved separately in DPBS and was then added to 
the GelMA/NP/TEA/VC solution to form the final precursor. To form the 
hydrogels, 70 µL of the prepolymer solution containing NPs was pipetted 
into polydimethylsiloxane (PDMS) cylindrical molds (diameter: 6 mm; 
height: 2.5 mm) for compressive tests or rectangular molds (12.5 × 4.5 × 
1.25 mm) for tensile test. The solutions were then photo-polymerized 
via exposure to visible light (450–520 nm) for 240 s, using an LS1000 
FocalSeal Xenon Light Source (Genzyme). Hydrogels were synthesized 
using different ratios of NPs to GelMA (i.e., 0, 1.3, 2.6, and 5%(w/w)). 
The compressive tests and tensile tests were performed according to the 
previously published methods.[35]
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Evaluation of In Vitro Swelling Ratio and Degradation: The swellability 
of GelMA/NP hydrogels was defined by calculating the ratio of weight 
change of the swollen hydrogel to the initial weight of the hydrogel in 
the dry state. For this, GelMA/NP hydrogels were incubated in DPBS at 
37 °C and weighed at different time points for up to 48 h. GelMA/NPs 
hydrogels were prepared as described in the previous section. Next, 
samples were lyophilized and their initial (dry) weight was measured. 
After incubation for each time point, the excess buffer was gently 
removed using a disposable wipe, and the wet weight was measured.
To evaluate the percentage of in vitro degradation, GelMA/NP 
hydrogels were lyophilized, weighed, and placed in Eppendorf tubes 
containing 1 mL of DPBS at 37 °C for 2 weeks. The DPBS solutions 
were changed every 2 days. The samples were then freeze dried and 
weighed on days 1, 4, 7, and 14 postincubation (n = 4). Similarly, for 
in vitro enzymatic degradation tests, hydrogels were placed in 1 mL of 
DPBS containing 0, 2.5, 5, 10, 40, 70, and 100 µg/mL collagenase type II. 
The enzyme-containing solutions were changed every 3 days, and 
samples were lyophilized on 1, 2, 4, 7, and 14 days postincubations. The 
percentage of degradation of the gels was determined using Equation (1)
Degradation % 1000
0
W W
W
t( ) = − ×  (1)
where W0 is the initial sample dry weight, and Wt is the dry weight after 
time t.
SEM Imaging: The samples for SEM imaging were dehydrated 
through an ascending series of ethanol in water solutions (30, 50, 70, 
90, and 100% (v/v)) and were then dried using a critical point dryer. 
SEM images of pristine GelMA and GelMA/NP/miR-223* hydrogels 
were obtained using a Hitachi S-4800 scanning electron microscope.
In Vitro Release Study: GelMA/NP containing different concentrations 
of NPs (1.3, 2.6, and 5%(w/w)) were formed on the upper layer of the 
transwell membranes. NPs were formed at different miRNA to polymer 
ratio (1:84, 1:169, 1:325 respectively for 1.3, 2.6, and 5%(w/w)). Next, 
transwell membranes containing GelMA/NP hydrogels were submerged 
into 1 mL of DPBS in 12-well plates. The concentration of miRNA in the 
solution was then assessed using a Quant-iT RiboGreen RNA Assay Kit 
at 1, 3, 6, 12, 24, 48, and 72 h postincubation at 37 °C.
The release test was also performed under enzymatic degradation 
conditions for GelMA/NP/negative miRNA at different concentrations 
of NPs (1.3, 2.6, 5%(w/w)) in GelMA. The hydrogels were formed on 
the upper layer of transwell membrane and were then submerged into 
a 12-well plate filled with 1 mL collagenase type II solution in DPBS 
(100 µg mL−1). Next, the concentration of miRNA in solution was 
measured at 3, 6, 12, 24, 48, and 72 h postincubation at 37 °C using a 
Quant-iT RiboGreen RNA Assay Kit.
NP/miRNA Stability and Nuclease Protection Assay: To test the stability 
of miR-223* in HA NPs, intact miR-223*, miR-223* loaded NPs and 
de-complexed miR-223* (released from NPs using PAA) were run on 4% 
EX E-gels (Invitrogen). Briefly, the miRNA was de-complexed from NPs 
by using an equal volume of 4% PAA (strongly negatively charged) and 
vortex mixing.[59] The mixture was then kept at room temperature for 
30 min and was later centrifuged at 11 000 g for 2 min. The supernatant 
containing released miRNA was loaded on 4% EX E-gels (Invitrogen). 
Ultralow range DNA ladder was loaded as a marker. For nuclease 
protection assay, naked miR-223*, miR-223*/NP, and PAA released miR-
223* from NPs were incubated with 20 µL of RNase A (0.03 U mL−1) for 
1 h at 37 °C, and the samples were run on 4% EX E-gels for evaluation 
of miRNA protection.
In Vitro Burst Pressure: The burst pressure of GelMA/NP and 
commercially available surgical sealants Evicel (Ethicon, Somerville, NJ, 
USA) and Coseal (Baxter, Deerfield, IL, USA) were measured based on 
the standard ASTM F2392-04 testing methodology. Porcine intestine 
(Savenor’s Market) was cut to a dimension of 40 mm × 40 mm. Next, 
the porcine intestine was placed between two stainless steel plates 
(35 mm × 35 mm), in which the upper piece had a 10 mm diameter hole 
in its center and a circular defect (2 mm in diameter) was created on the 
center of the porcine intestine (Figure S10A, Supporting Information). 
20 µL of the adhesive was injected on the defect and, in the case of 
GelMA, the precursor was exposed to visible light. Next, the porcine 
intestine was placed into the burst pressure testing system, consisting 
of a pressure sensor, and a recording unit. Air was then applied using a 
syringe pump at a rate of 5 mL s−1 to the sample until bursting (n ≥ 5).
In Vitro Wound Closure: The adhesion strengths of GelMA/NP, Evicel 
and Coseal were evaluated according to a modified ASTM testing 
methodology (ASTM F2458-05). Briefly, fresh porcine skin was obtained 
from a local slaughterhouse and after removing the adipose tissue layer, 
the skin samples were cut into rectangular sections (10 mm × 15 mm). 
The porcine skin was kept moist with DPBS prior to use. The tissues 
were fixed onto two precut glass slides (30 mm × 60 mm) using Krazy 
Glue. The tissue was then cut from the middle with a single edge cutter 
blade. Afterward, 40 µL of the precursor solution or the commercial 
adhesives was pipetted onto the tissue interface and subsequently 
cross-linked with visible light (Figure S10B, Supporting Information). 
The commercial sealants were applied according to instructions from 
the manufacturer. Maximum adhesive strength of each sample was 
obtained at the point of tearing by using an Instron mechanical tester.
In Vitro Lap Shear: The shear strength of GelMA/NP, Evicel and Coseal 
was evaluated according to the standard testing methodology (ASTM 
F2255-05). Two precut glass slides (10 mm × 50 mm) were used to 
hold the adhesives. One end of each glass slides (10 mm × 15 mm) was 
coated with gelatin from porcine skin (20%(w/v) in distilled water) that 
was dried at room temperature before adding the adhesive precursors. 
Afterward, 10 µL of the desired solution was added on the gelatin-coated 
region of a precut glass slide, and then another gelatin-coated glass 
slide was placed over the precursor solution (Figure S10C, Supporting 
Information). After assembly, the GelMA/NP hydrogel between the two 
gelatin-coated regions of the two glass slides was photo-crosslinked 
by visible light. The two glass slides were placed into the grips of an 
Instron mechanical tester for shear testing. For this, tensile loading with 
a strain rate of 10 mm min−1 was applied to the samples. The point of 
detachment of the two glass slides was measured and reported as the 
shear strength (n ≥ 5).
In Vitro Cell Studies: J774A.1 murine macrophages were cultured at 
37 °C and 5% CO2 in DMEM culture media supplemented with 10%(v/v) 
FBS and 1%(v/v) penicillin/streptomycin. For toxicity test, 200 000 cells 
were seeded in 12-well plates and then allowed to attach for 24 h before 
applying the hydrogels. 150 µL of the precursor solution containing 
GelMA/NP/miR-223* were photo-crosslinked on the membrane of 
transwell inserts (75 mm polycarbonate inserts with a 1.0 µm pore size). 
After photo-crosslinking, the inserts were placed into the 12-well plates 
containing J774A.1 macrophages. Each well was filled with 850 µL of 
DMEM, and another 150 µL of media was added to the upper layer of 
the transwell insert.
3D encapsulation of NIH3T3 fibroblasts was carried out using a 
protocol described in the previous publication.[35] Briefly, precursor 
GelMA/NP/miR-223* solutions were prepared in cell culture media 
containing TEA (1.875% w/v) and VC (1.25% w/v), and gently mixed 
with NIH3T3 cells (5 × 106 cells per mL). A 10 µL drop of this mixture 
was pipetted on a 150 mm spacer, and covered by a TMSPMA-coated 
glass slide. After photo-crosslinking, the hydrogels were washed several 
times with warm media to remove the unreacted photoinitiators. The 
cell-laden hydrogels were then placed in 24-well plates and incubated at 
37 °C, 5% CO2, and humidified atmosphere.
Cell Viability and Proliferation Assays: Cell viability was determined 
using a calcein AM/ethidium homodimer-1 live/dead kit (Invitrogen) 
according to instructions from the manufacturer. Cell viability was 
evaluated on days 1, 3, and 5 postincubation with GelMA/NP/miRNA 
(n ≥ 6). Fluorescent images were taken using a Zeiss Axio Observer 
Z1 inverted microscope and were analyzed using the ImageJ software. 
Cell viability was calculated as the ratio of viable cells to the total 
number of live and dead cells. The PrestoBlue assay was used to 
evaluate the metabolic activity of cells according to instructions from 
the manufacturer on days 1, 3, and 5 postincubation with GelMA/NP/
miRNA (n ≥ 6). Fluorescence intensity of the resulting solutions was 
recorded at 535–560 nm excitation and 590–615 nm emission.
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In Vitro miRNA Transfection and Macrophage Polarization: For 
transfection and polarization studies, 200 000 J774A.1 macrophages 
were cultured on 12-well plates and were first polarized toward the M1 
(proinflammatory) phenotype by overnight incubation with LPS + IFN-γ 
(100 ng mL−1) using the previously published method.[59] The cells 
were then transfected with i) GelMA/blank NP, ii) GelMA/NP/negative 
miRNA, and iii) GelMA/NP/miR-223* (5.0%(w/w)) cross-linked on 
the transwell insert. The cells were then processed for RNA isolation 
on 24, and 48 h postincubation at 37 °C, using Quick-RNA MiniPrep 
RNA isolation kit (Zymo Research Corp., Irvine, CA). The efficiency 
of transfection was assessed using a Taqman miR-223 specific assay 
(Thermo Fischer scientific) via qPCR (LightCycler 480, Roche, Branford, 
CT). U6 small nuclear RNA (snRNA) was used as a housekeeping gene. 
The changes in the levels of expression of iNOS2 (M1/proinflammatory 
marker) and Arg1 (M2/anti-inflammatory marker) were quantified using 
qPCR (iTaq Universal SYBR Green supermix, Biorad, CA).[59] β-actin 
was used as a housekeeping gene. The levels of expression of the 
proinflammatory cytokine’s TNF-α, IL-1β, and IL-6 were quantified by 
using qPCR.[59] β-actin was used as a housekeeping gene. Primers are 
listed in Table S1 in the Supporting Information.
Full-Thickness In Vivo Wound Model: All animal protocols were approved 
by the Institutional Animal Care and Use Committee (ICAUC; protocol 
17-0516R) at Northeastern University (Boston, MA, USA). CD-1 male 
mice (7 to 8 week old, average wt. 30 g) were purchased from Charles 
River (MA, USA). Animals were housed for at least 48 h prior to the 
surgery at the animal facilities with 12 h light/dark cycles, and food and 
water ad libitum. 24 h before the surgery, the dorsal skin of the animals 
was shaved, and the remaining hair was removed using a commercial 
hair-removing cream. On surgery day, the animals were anesthetized via 
inhalation of 4% isoflurane in an induction chamber. Following induction, 
the animals were positioned in ventral recumbency on top of a heating 
blanket at 37 °C to stabilize their body temperature and connected 
to a breathing circuit (2% isoflurane) for maintenance of anesthesia. 
5–10 mg kg−1 of Meloxicam in 150 µL of sterile saline was administered 
subcutaneously prior to the incision. Following analgesia, the surgical site 
was disinfected using three consecutive applications of iodine and 70% 
ethanol. 6 mm sterile biopsy punches were used to create bilateral full-
thickness wounds on the dorsum of the mice, and silicon splints (inner 
diameter = 6 mm, outer diameter = 9 mm, thickness = 1 mm) were then 
sutured on top of each wound.[60] The animals were assigned randomly to 
two endpoints and four groups for analysis: i) DPBS control (DPBS), ii) 
pure GelMA hydrogels (GelMA), iii) GelMA/NP negative miRNA control 
(Neg miRNA) and iv) GelMA/NP miR-233* (5.0%(w/w) NPs to GelMA 
concentration). For animals receiving the DPBS control, 50 µL of sterile 
DPBS was pipetted on top of each wound. For animals receiving control 
and treatment GelMA hydrogels, 50 µL of the hydrogel precursor was 
pipetted on the wound area and photocross-linked in situ with visible 
light for 4 min. The wound beds were then covered with Tegaderm films 
and protected using cohesive bandages. Meloxicam (5–10 mg kg−1) 
was administered subcutaneously after the procedure for analgesia, 
followed by placing the mice under a warming lamp until recovered from 
anesthesia.
The animals were weighed and monitored daily for signs of pain or 
discomfort, and digital photographs were acquired for all wounds to 
monitor wound closure. Following administration of the treatments, 
the wounds were covered with a protective Tegaderm film and a 
cohesive bandage. No additional administrations were carried out, 
and the adhesive Tegaderm film was not changed to avoid additional 
trauma to the wound site. Changes in the wound area, relative to the 
corresponding initial measurement, were calculated using ImageJ to 
compare the rate of wound closure among the experimental groups. 
On days 2, 5, and 12 postsurgery, animals were euthanized via CO2 
inhalation followed by cervical dislocation. Following euthanasia, the 
full-thickness wounds (n = 6 wounds for each group) and 1–2 mm 
of the adjacent skin were harvested for qRT-PCR analysis and 
histopathological examination.
Morphological Assessment and Histopathological Evaluation: Wound 
biopsies with hydrogels were fixed in 10% formalin for 24 h. They were 
then incubated in 30% sucrose solution overnight, followed by overnight 
incubation in 100% FBS. Next, wound biopsies were flash-frozen in 
liquid nitrogen in Optimal Cutting Temperature (OCT) Compound. 9 µm 
cryosections were acquired using a Leica Biosystems CM3050 S Research 
Cryostat and processed with hematoxylin-eosin and Masson’s trichrome 
staining as well as immunofluorescence staining. Tissue sections were 
stained with primary antibodies against CD31, F4/80, and CD206, and an 
Alexa Fluor 594-conjugated secondary antibody was used for detection. 
For evaluation of the number of microvessels (CD31), endothelial 
cell or endothelial-cell cluster that was clearly separated from adjacent 
microvessel was considered a single countable microvessel (4 mm2 of 
the wounds’ center).[61] All sections were counterstained with DAPI, and 
visualized on an Axio Observer Z1 inverted microscope (n = 3).
Total RNA Isolation and qPCR Analysis: The wound biopsy samples 
were excised and stored in RNA later at −20 °C before further processing. 
For RNA isolation, the tissue samples were triturated using a mortar and 
pestle under liquid nitrogen. Total RNA was isolated from the triturated 
samples using TRI reagent (Fischer scientific) following the instructions 
from the manufacturer. RNA (1 µg) was reversely transcribed into 
cDNA and was used for qPCR analysis using SYBR green supermix 
reagent. The expression of Arg1 and iNOS2 was quantified using a 
7300 Real-Time PCR System from Applied Biosystems. Glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) was used as a housekeeping 
gene. The comparative CT method was used to analyze the expression of 
Arg1 and iNOS2 mRNA.
Data Analysis: Data analysis was carried out using a 1- or 2-way 
ANOVA test with GraphPad Prism 6.0 software. Error bars represent 
mean ± standard deviation (SD) of measurements (*p < 0.05, 
**p < 0.01, ***p < 0.001, and ****p < 0.0001).
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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